Supplementation of a Leucine-enriched Protein Blend
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03796897 |
|
Recruitment Status : Unknown
Verified February 2020 by Stuart Phillips, McMaster University.
Recruitment status was: Recruiting
First Posted : January 8, 2019
Last Update Posted : February 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Dietary Modification Diet Habit | Dietary Supplement: Leucine-enriched protein Behavioral: Habitual diet only | Early Phase 1 |
In a cross-over, randomized controlled trial, 10 healthy young participants (5 men and 5 women) will be recruited to undergo exercise resistance training randomized to habitual diet or habitual diet and supplementation (2 x per training session). For two of the training sessions the investigators will utilize a uni-lateral resistance exercise model to identify the acute effects of exercise and exercise + supplementation on the integrated rate of myofibrillar MPS within subject. This model enhances statistical power and eliminates between-subject differences impacting our outcomes. Throughout the study participants will record their macronutrient dietary intake. In addition, baseline body composition will be assessed with dual-energy x-ray absorptiometry.
Visit 1 (Day -7): Familiarization, strength testing and baseline body composition One week before the exercise trial, the investigators will ask participants to visit McMaster University to undergo a familiarization session with the exercise equipment and to perform 3-5 repetition maximum strength testing. This will allow the investigators to calculate the resistance (weight) participants will lift in their upcoming training sessions. The investigators will also perform a body composition scan using a dual-energy x-ray absorptiometry (DXA), assess participants' height and weight, and administer daily food logs with instructions to assess their habitual diet.
Visit 2 (Day 0): D2O administration and resting blood and saliva sampling One week after the familiarization visit, the investigators will ask participants to come to McMaster University in a fasted state and receive a dose of doubly labelled water D2O equal to 0.8mLs/kgBW and every hour for 3 hours after providing a blood and saliva sample. D2O is a safe, and widely used stable isotope, used to effectively measure the rate at which participants' muscle grow.
Visits 3 and 7 (Days 1 and 7): Resistance training program and muscle biopsy On these days participants will come to the lab in the morning following their habitual diet routine and will have a resting biopsy, blood and saliva samples taken. Next, participants may be asked to consume the supplement but will be asked to drink a small amount of D2O. Finally, participants will perform a combination resistance style exercise training session and immediately following training may be asked to consume the supplement.
Visit 4, 5, 8 & 9 (Days 2, 3, 8, 9): Resistance training program On these days participants will come to the lab in the morning following their habitual diet routine and have a saliva sample taken. Next, participants may be asked to consume the supplement but will be asked to drink a small amount of D2O. Finally, participants will perform a combination resistance style exercise training session and immediately following training participants may be asked to consume the supplement.
Visits 6 and 10 (Days 4 and 10): Uni-lateral acute training session and muscle biopsy On these days participants will come to the lab in the morning following their habitual diet routine. First, participants may be asked to consume the supplement immediately before performing a uni-lateral acute resistance training session. Participants will be asked to drink a small amount of D2O but only during Visit 6 (Day 4). Immediately following training, participants may be asked to consume the supplement. One hour following exercise participants will have a muscle biopsy, blood and saliva samples taken.
Days 5 and 6 (see attached study timeline): Washout period The investigators will ask that participants drink one aliquot of D2O on day 5 and one aliquot of D2O on day 6. One hour after participants drink the aliquot of D2O the investigators ask that participants take their own saliva sample at home (D2O aliquots and a sampling kit will be provided with instructions).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 10 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | Supplementation of a Leucine-Enriched Dairy Protein Blend: Chronic and Acute Metabolic Responses in Young Men and Women |
| Actual Study Start Date : | June 1, 2019 |
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | February 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Leucine-enriched protein + exercise
whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein), vitamin D, and free leucine
|
Dietary Supplement: Leucine-enriched protein
Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions) |
|
Sham Comparator: Habitual diet + exercise
habitual diet only
|
Behavioral: Habitual diet only
Habitual diet only (no supplementation) for 4 exercise sessions |
- Integrated Muscle Protein Synthetic Rate [ Time Frame: 10 days ]oral deuterium consumption: Isotope protocol (See ref., PMID 23821570)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 29 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Be between the ages of 18-29 years (inclusive)
- Be able to maintain a habitual diet, physical activity patterns, and body mass throughout the trial
- Be in general good health
- Be able to participate in resistance training and aerobic training
- Understand the study procedures and sign this form providing informed consent to participate in the study
- Be able to consume a protein bar in the allotted time frame of 10 minutes
Exclusion Criteria:
- Smoker
- Excessive alcohol consumption (more than 21 units of alcohol / week; 1 unit of alcohol is approximately 25 mL of spirits (40% alcohol), 250 mL of beer (4% alcohol) or 75 mL of wine (13% alcohol))
- Have health problems such as: renal or gastrointestinal disorders, metabolic disease, heart disease, vascular disease, rheumatoid arthritis, diabetes, poor lung function, uncontrolled blood pressure, dizziness, thyroid problems, or any other health conditions for which you are being treated that might put you at risk for this study
- Have a known or suspected allergy to local anesthetics such as lidocaine
- Have a dairy protein allergy
- Participation in another nutrition or exercise research study
- Do not understand English or have a condition the PI believes would interfere with a participants' ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put someone at undue risk
- Use of medications known to affect protein metabolism (i.e. corticosteroids, or prescription strength acne medications)
- Consuming a vegan diet
- Use of an investigational drug product or nutraceutical within the last 30 days
- Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigators, would compromise the ability to comply with the study requirements
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03796897
| Contact: Stuart M Phillips, PhD | 905-525-9140 ext 24465 | phillis@mcmaster.ca | |
| Contact: Daniel A Traylor, PhD | traylord@mcmaster.ca |
| Canada, Ontario | |
| Exercise Metabolism Research Laboratory, McMaster Univeristy | Recruiting |
| Hamilton, Ontario, Canada, L8S 4K1 | |
| Contact: Stuart M Phillips, Ph.D. 905-525-9140 ext 24465 phillis@mcmaster.ca | |
| Principal Investigator: Stuart M Phillips, Ph.D. | |
| Responsible Party: | Stuart Phillips, Professor, McMaster University |
| ClinicalTrials.gov Identifier: | NCT03796897 |
| Other Study ID Numbers: |
5706 |
| First Posted: | January 8, 2019 Key Record Dates |
| Last Update Posted: | February 7, 2020 |
| Last Verified: | February 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |

